Literature DB >> 32077346

Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives.

Corrado Pelaia1, Alessandro Vatrella2, Angela Sciacqua3, Rosa Terracciano4, Girolamo Pelaia1.   

Abstract

Introduction: The p38 serine-threonine kinases are members of the large family of mitogen-activated protein kinases (MAPK). In particular, p38 MAPK subgroup includes four isoforms (α, β, γ, δ), among which p38α and p38β are mainly involved in inflammatory disorders. Indeed, by activating key transcription factors and by inducing the expression of several cytokines and chemokines, p38α plays a central role in the pathobiology of chronic obstructive pulmonary disease (COPD).Areas covered: This concise review focuses on the contribution of p38 MAPK to development, maintenance, and amplification of chronic lung inflammation in COPD. Moreover, we discuss the potential role of p38 MAPK as suitable target for perspective therapeutic approaches under evaluation as potential new COPD treatments. In this regard, an extensive literature search has been conducted throughout PubMed source (1990-2020).Expert opinion: Despite some promising preclinical data, so far the results of clinical trials evaluating p38 MAPK inhibitors have been quite disappointing, thus suggesting a cautious judgment about the future perspectives of these drugs for COPD therapy.

Entities:  

Keywords:  COPD; lung inflammation; p38 MAPK; p38 inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32077346     DOI: 10.1080/17476348.2020.1732821

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  7 in total

Review 1.  Pathological Mechanism and Targeted Drugs of COPD.

Authors:  Peng Guo; Rui Li; Tie Hua Piao; Chun Lan Wang; Xiao Lu Wu; Hong Yan Cai
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-12

Review 2.  Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies.

Authors:  Corrado Pelaia; Alessandro Vatrella; Luca Gallelli; Nicola Lombardo; Angela Sciacqua; Rocco Savino; Girolamo Pelaia
Journal:  Drug Des Devel Ther       Date:  2021-03-23       Impact factor: 4.162

Review 3.  The future of inhalation therapy in chronic obstructive pulmonary disease.

Authors:  Mario Cazzola; Josuel Ora; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-02-17

4.  Blood miRNAs Are Linked to Frequent Asthma Exacerbations in Childhood Asthma and Adult COPD.

Authors:  Anshul Tiwari; Brian D Hobbs; Jiang Li; Alvin T Kho; Samir Amr; Juan C Celedón; Scott T Weiss; Craig P Hersh; Kelan G Tantisira; Michael J McGeachie
Journal:  Noncoding RNA       Date:  2022-04-03

5.  Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD.

Authors:  Haichuan Yu; Xiaojie Su; Ting Lei; Lu Zhang; Zhouzhou Feng; Chuchu Zhang; Meng Zhang; Yalei Wang; Xinlong Chen; Jian Liu
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

Review 6.  Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.

Authors:  Suchi Gupta; Vishnu Krishnakumar; Yashvi Sharma; Amit Kumar Dinda; Sujata Mohanty
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 6.692

Review 7.  Why do some asthma patients respond poorly to glucocorticoid therapy?

Authors:  Ishbel Henderson; Elisabetta Caiazzo; Charles McSharry; Tomasz J Guzik; Pasquale Maffia
Journal:  Pharmacol Res       Date:  2020-09-08       Impact factor: 7.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.